Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 46 to 60 of 206 results for dementia

  1. Social care trainers' resource

    (guideline CG170). Dementia Supporting people with dementia and their carers in health and social care (guideline CG42)...

  2. Anticholinergic burden:- Does actively reducing anticholinergic burden in people living with dementia improve cognitive outcomes compared with usual care?

    burden:- Does actively reducing anticholinergic burden in people living with dementia improve cognitive outcomes compared with usual...

    Research recommendation
    Published
    19 December 2018

  3. NICE's strategic priorities in 2026 to 2027

    Over the next year, our prioritisation decisions will be shaped by the government’s strategic direction for health and life sciences, and by the needs of the NHS, local systems and the people who use services.

  4. Transition between inpatient hospital settings and community or care home settings for adults with social care needs (NG27)

    This guideline covers the transition between inpatient hospital settings and community or care homes for adults with social care needs. It aims to improve people's experience of admission to, and discharge from, hospital by better coordination of health and social care services.

    NICE guideline
    Published
    1 December 2015
    View recommendations

    Sections for NG27

  5. Discharging people from hospital

    conditions guideline People's experience in adult social care guideline Dementia guideline Care of dying adults guideline Home care...

  6. Combination treatment for Parkinson's disease dementia:- What is the effectiveness of combination treatment with a cholinesterase inhibitor and memantine for people with Parkinson's disease dementia if treatment with a cholinesterase inhibitor alone is not effective or no longer effective?

    NG71/1 Question Combination treatment for Parkinson's disease dementia:- What is the effectiveness of combination treatment with a...

    Research recommendation
    Published
    15 October 2018

  7. Improving wellbeing in care homes

    conditions guideline People's experience in adult social care guideline Dementia guideline Care of dying adults guideline Home care...

  8. Taking a person-centred approach to rehabilitation

    conditions guideline People's experience in adult social care guideline Dementia guideline Care of dying adults guideline Home care...

  9. How strong are the associations between hearing and visual loss, and sleep patterns and positive and negative health outcomes, in particular the development of dementia, disability and frailty? What are the most effective and cost-effective interventions to protect hearing and vision and improve sleep and what is their effect on the development of dementia, disability and frailty?

    positive and negative health outcomes, in particular the development of dementia, disability and frailty? What are the most effective...

    Research recommendation
    Published
    9 December 2015

  10. Donepezil, galantamine, rivastigmine and memantine for the treatment of Alzheimer's disease (TA217)

    Evidence-based recommendations on donepezil (Aricept), galantamine (Reminyl), rivastigmine (Exelon) and memantine (Ebixa) for treating Alzheimer's disease in adults.

    Technology appraisal guidance
    Last updated
    20 June 2018
    View recommendations

    Sections for TA217

  11. Anticholinergic burden:- Does actively reducing anticholinergic burden in people living with dementia improve cognitive outcomes compared with usual care?

    burden:- Does actively reducing anticholinergic burden in people living with dementia improve cognitive outcomes compared with usual...

    Research recommendation
    Published
    10 December 2018

  12. Blarcamesine for treating mild cognitive impairment or mild dementia caused by Alzheimer's disease [ID6679]

    Awaiting development Reference number: GID-TA11717 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  13. Semaglutide for treating mild cognitive impairment or mild dementia caused by Alzheimer's disease [ID6635]

    Awaiting development Reference number: GID-TA11847 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  14. Case management:- What is the effectiveness and cost effectiveness of high-intensity case management compared with usual care on quality of life (for the person living with dementia and for their carers) and the timing of entry to long-term care?

    compared with usual care on quality of life (for the person living with dementia and for their carers) and the timing of entry to...

    Research recommendation
    Published
    10 December 2018

  15. Digital technologies for the early detection and initial diagnosis of adult hearing loss (provisional title)

    In development Reference number: GID-HTG10172 Expected publication date: TBC

    HealthTech guidance
    In development